Page 252 - Clinical Immunology_ Principles and Practice ( PDFDrive )

CHaPtEr 15 Immunoglobulin Function 233

oN tHE HorIZoN 7. James LC, Roversi P, Tawfik DS. Antibody multispecificity mediated by
conformational diversity. Science 2003;299:1362–7.
Recombinant Antibodies—Antibody Engineering 8. Kwong P, Doyle M, Casper D, et al. HIV-1 evades antibody-mediated
neutralization through conformational masking of receptor-binding sites.
• Enhance effector function potency and half-life through Fc Nature 2002;420:678–82.
modification.
• Reduce or eliminate bystander effects. 9. Mollnes TE, Harboe M. Neoepitope expression during complement
• Isolate and express antibody genes using single B-cell cloning or activation—a model for detecting antigenic changes in proteins and
combinatorial libraries. activation of cascades. The Immunologist 1993;1:43–9.
• Allow expansion of the antibody repertoire and targeting 10. Berzofsky JA. Intrinsic and extrinsic factors in protein antigenic structure.
possibilities. Science 1985;229:932–40.
• Facilitate agents for molecular recognition of minimal size (i.e., 11. Horiya S, MacPherson IS, Kruas IJ. Recent strategies targeting HIV
nanobodies). glycans in vaccine design. Nat Chem Biol 2014;10:990–9.
• Develop drugs or toxins that can be covalently attached to novel 12. Mannik M. Physicochemical and functional relationships of immune
antibodies for therapy. complexes. J Immunol 1980;74:333–8.
• Create multispecific or multimeric constructs. 13. Heyman B. The immune complex: possible ways of regulating the
• Guide vaccine design. antibody response. Immunol Today 1990;11:310–13.
• Evaluate the roles of isotypes in protection or other functions. 14. Dimmock NJ. Neutralization of animal viruses. Curr Top Microbiol
• Define how differences in glycosylation can alter effector function. Immunol 1993;183:1–149.
15. Mazanec MB, Kaetzel CS, Lamm ME, et al. Intracellular neutralization of
virus by immunoglobulin A antibodies. Proc Natl Acad Sci USA
1992;89:6901–5.
oN tHE HorIZoN 16. Binder GK, Griffin DE. Immune-mediated clearance of virus from the
Immunity Through Vector-Mediated Expression central nervous system. Microbes Infect 2003;5(5):439–48.
of Antibodies (Vectored Immunoprophylaxis) 17. Lowy I, Molrine DC, Leav BA, et al. Treatment with monoclonal
antibodies against Clostridium difficile toxins. N Engl J Med
• Host muscle cells transduced with a viral vector encoding antigen- or 2010;362:197–205.
pathogen-specific antibodies. 18. Abboud N, Chow SK, Saylor C, et al. A requirement for FcgR in
• For highly variable pathogens, such as human immunodeficiency virus antibody-mediated bacterial toxin neutralization. J Exp Med
(HIV)-1, the antibodies are preferably broadly neutralizing. 2010;207:2395–405.
• Based on model systems in mice, vector-mediated antibody expression 19. Garred P, Michaelsen TE, Aase A. The IgG subclass pattern of
can be long-term without immunization. complement activation depends on epitope density and antibody and
• Antibodies carrying different variable domains and expressing overlap- complement concentration. Scand J Immunol 1989;30:379–82.
ping reactivities can potentially be simultaneously expressed. 20. Tan LK, Shopes RJ, Oi VT, et al. Influence of the hinge region on
complement activation, C1q binding, and segmental flexibility in
chimeric human immunoglobulins. Proc Natl Acad Sci USA
to encode protective antibodies in viral expression vectors that 1990;87:162–6.
can be introduced into experimental animals and probably 21. Nimmerjahn F, Ravetch JV. Fcγ receptors as regulators of immune
responses. Nat Rev Immunol 2008;8:34–47.
humans and make possible the long-term expression of these 22. Monteiro RC. Role of IgA and IgA fc receptors in inflammation. J Clin
mediators of immunity at relevant serum concentrations. 30 Immunol 2010;30:1–9.
23. Kaetzel CS, Robinson JK, Chintalacharuvu KR, et al. The polymeric
Please check your eBook at https://expertconsult.inkling.com/ immunoglobulin receptor (secretory component) mediates transport of
for self-assessment questions. See inside cover for registration immune complexes across epithelial cells: a local defense function for
details. IgA. Proc Natl Acad Sci USA 1991;88:8796–800.
24. Greenspan NS. Reflections on internal images. Nat Biotechnol
1997;15:123–4.
REFERENCES 25. Cragg MS, French RR, Glennie MJ. Signaling antibodies in cancer
therapy. Curr Opin Immunol 1999;11:541–7.
1. Amit AG, Mariuzza RA, Phillips SEV, et al. Three-dimensional structure
of an antigen-antibody complex at 2.8 Å resolution. Science 26. Kohler G, Milstein C. Continuous cultures of fused cells secreting
1986;233:747–53. antibody of predefined specificity. Nature 1975;256:495–7.
2. Greenspan NS. Dimensions of antigen recognition and levels of 27. Morrison SL. In vitro antibodies: strategies for production and
immunological specificity. Adv Cancer Res 2001;80:147–87. application. Annu Rev Immunol 1992;10:239–65.
3. Steward MW. The biological significance of antibody affinity. Immunol 28. Hudson PJ. Recombinant antibody constructs in cancer therapy. Curr
Today 1981;2:134–9. Opin Immunol 1999;11:548–57.
4. Rini JM, Schulze-Gahmen U, Wilson IA. Structural evidence for induced 29. Corti D, Lanzavecchia A. Broadly neutralizing antiviral antibodies. Annu
fit as a mechanism for antibody–antigen recognition. Science Rev Immunol 2013;31:705–42.
1992;255:959–65. 30. Schnepp BC, Johnson PR. Vector-mediated in vivo antibody expression.
5. Holmberg D, Forsgren S, Forni L, et al. Reactions among IgM antibodies Microbiol Spectr 2014;2.
derived from neonatal mice. Eur J Immunol 1984;14:435–41.
6. Kramer A, Keitel T, Winkler K, et al. Molecular basis for the binding
promiscuity of an anti-p24 (HIV-1) monoclonal antibody. Cell
1997;91:799–809.